Octernal Therapeutics shares are trading lower. The company announced updated data from its Phase 1/2 Study of ONCT-534 for the treatment of patients with relapsed or refractory metastatic Castration-Resistant Prostate Cancer.
Portfolio Pulse from Benzinga Newsdesk
Octernal Therapeutics shares declined following the release of updated data from its Phase 1/2 study of ONCT-534, targeting relapsed or refractory metastatic Castration-Resistant Prostate Cancer.
October 22, 2024 | 4:32 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Octernal Therapeutics shares fell after the company released updated data from its Phase 1/2 study of ONCT-534, which is aimed at treating relapsed or refractory metastatic Castration-Resistant Prostate Cancer.
The decline in Octernal Therapeutics' stock price is likely due to investor reaction to the updated data from the ONCT-534 study. Such data releases can significantly impact biotech stocks, especially if the results do not meet investor expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100